Silencing of Abcc8 or inhibition of newly upregulated Sur1-Trpm4 reduce inflammation and disease progression in experimental autoimmune encephalomyelitis

Table 1 Summary of EAE clinical scores

Group	Disease incidence/total (%)	Number of deaths	Disease onset (days)^a	Mean clinical scores
Group	Disease incidence/total (%)	Number of deaths	Disease onset (days)^a	Day 15^b	Day 20^c	Day 25^c	Day 30^c	Day 9–30^d
WT/EAE	10/10 (100)	2	11.8 ± 0.36	2.1 ± 0.38	3.1 ± 0.46	3.0 ± 0.45	3.1 ± 0.48	2.34 ± 0.23
WT/EAE + GLIB	10/10 (100)	1	12.9 ± 0.50	1.3 ± 0.34	1.0 ± 0.34	1.0 ± 0.33	1.1 ± 0.35	0.94 ± 0.08
Abcc8−/−/EAE	10/10 (100)	0	13.0 ± 0.41	1.8 ± 0.36	1.4 ± 0.31	1.3 ± 0.26	1.0 ± 0.29	1.16 ± 0.12

Values are presented as mean ± SEM (10 mice per group)
^aDisease onset is defined as the first day of a clinical score of one or more. There was no statistically significant difference in day of onset of disease between the groups
^bThere was no statistically significant difference in scores between the groups on day 15
^cOn day 20, 25, and 30, the mean clinical scores of mice were significantly lower in WT/EAE + GLIB and Abcc8−/−/EAE groups compared to WT/EAE group. (For all three time points: WT/EAE vs. WT/EAE + GLIB, P < 0.01; WT/EAE vs. Abcc8−/−/EAE, P < 0.01; N = 10; one-way ANOVA with Fisher’s post-hoc comparisons)
^dOverall Mean score during the disease phase (Day 9 to 30) is significantly lower in WT/EAE + GLIB and Abcc8−/−/EAE groups compared to WT/EAE group. (WT/EAE vs. WT/EAE + GLIB, P < 0.001; WT/EAE vs. Abcc8−/−/EAE, P < 0.001; N = 10; one-way ANOVA with Fisher’s post-hoc comparisons)

ISSN: 1742-2094